Journal of Molecular and Cellular Cardiology
Volume 49, Issue 4 , Pages 647-654 , October 2010

Il-19 reduces VSMC activation by regulation of mRNA regulatory factor HuR and reduction of mRNA stability

  • Anthony A. Cuneo
    • ,
  • David Herrick
    • ,
  • Michael V. Autieri

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Physiology, Temple University School of Medicine, Room 1050, MERB, 3500 N. Broad St., Philadelphia PA 19140, USA. Tel.: +1 215 707 1751; fax: 1 215 707 5737.

Received 5 April 2010 ,Revised 21 April 2010 ,Accepted 28 April 2010.

References 

  1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809
  2. Raines EW, Ferri N. Cytokines affecting endothelial and smooth muscle cells in vascular disease. J. Lipid Res. 2005;46:1081–1092
  3. Von der Thusen JH, Kuiper J, van Berkel TJ, Biessen EA. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol. Rev. 2003;55:133–166
  4. Singer C, Sonemany S, Baker K, Gerthoffer W. Synthesis of immune modulators by smooth muscles. BioEssays. 2004;26:646–655
  5. Tedgui A, Mallat Z. Anti-inflammatory mechanisms in the vascular wall. Circ. Res. 2001;88:877–887
  6. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc. Res. 2008;79:360–376
  7. Pinderski Oslund LJ, Hedrick CC, Olvera T, Hagenbaugh A, Territo M, Berliner JA, et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 1999;19:2847–2853
  8. Tian Y, Sommerville L, Cuneo A, Kelemen S, Autieri M. Expression and suppressive effects of interleukin-19 on vascular smooth muscle cell pathophysiology and development of intimal hyperplasia. Am. J. Pathol. 2008;173:901–909
  9. Gallagher G, Dickensheets H, Eskdale J, Izotova LS, Mirochnitchenko OV, Peat JD, et al. Cloning, expression and initial characterization of interleukin-19 (IL-19), a novel homologue of human interleukin-10 [IL-10]. Genes Immun. 2000;1:442–450
  10. Gallagher G, Eskdale E, Jordan W, Peat J, Campbell J, Boniotto M, et al. Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses. Int. Immunopharmacol. 2004;4:615–626
  11. Wahl C, Müller W, Leithäuser F, Adler G, Oswald F, Reimann J, et al. IL-20 receptor 2 signaling down-regulates antigen-specific T cell responses. J. Immunol. 2009;182:802–810
  12. Radu M, Soprano DR, Soprano KJ. S10 phosphorylation of p27 mediates atRA induced growth arrest in ovarian carcinoma cell lines. J. Cell. Physiol. 2008;217:558–568
  13. Barreau C, Paillard L, Osborne B. AU-rich elements and associated factors: are there unifying principles?. Nucleic Acids Res. 2005;33:7138–7150
  14. Lentsch A, Shanley T, Sarma V, Ward P. In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J. Clin. Invest. 1997;100:2443–2448
  15. Mazighi M, Pelle A, Gonzalez W, Mtairag el M, Philippe M, Henin D, et al. IL-10 inhibits vascular smooth muscle cell activation in vitro and in vivo. Am. J. Physiol. Heart Circ. Physiol. 2004;287:H866–H871
  16. Brown CY, Lagnado CA, Vadas MA, Goodall GJ. Differential regulation of the stability of cytokine mRNAs in lipopolysaccharide-activated blood monocytes in response to interleukin-10. J. Biol. Chem. 1996;271:20108–20112
  17. Rajasingh J, Bord E, Luedemann C, Asai J, Hamada H, Thorne T, et al. IL-10-induced TNF-alpha mRNA destabilization is mediated via IL-10 suppression of p38 MAP kinase activation and inhibition of HuR expression. Faseb J. 2006;20:2112–2124
  18. Pullmann R, Juhaszova M, Lopez de Silanes I, Kawai T, Mazan-Mamczarz K, Halushka MK, et al. Enhanced proliferation of cultured human vascular smooth muscle cells linked to increased function of RNA-binding protein HuR. J. Biol. Chem. 2005;280:22819–22826
  19. Fan XC, Steitz JA. Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. Embo J. 1998;17:3448–3460
  20. Pascale A, Amadio M, Scapagnini G, Lanni C, Racchi M, Provenzani A, et al. Neuronal ELAV proteins enhance mRNA stability by a PKC alpha-dependent pathway. Proc. Natl Acad. Sci. USA. 2005;102:12065–12070
  21. Doller A, Huwiler A, Müller R, Radeke HH, Pfeilschifter J, Eberhardt W. Protein kinase C alpha-dependent phosphorylation of the mRNA-stabilizing factor HuR: implications for posttranscriptional regulation of cyclooxygenase-2. Mol. Biol. Cell. 2007;18:2137–2148
  22. Mazighi M, Pelle A, Gonzalez W, Mtairag ElM, Philippe M, Henin D, et al. IL-10 inhibits vascular smooth muscle cell activation in vitro and in vivo. Am. J. Physiol. Heart Circ. Physiol. 2004;H866–H871
  23. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Ann. Rev. Immunol. 2004;22:929–979
  24. Bakheet T, Frevel M, Williams BR, Greer W, Khabar KS. ARED: human AU-rich element-containing mRNA database reveals an unexpectedly diverse functional repertoire of encoded proteins. Nucleic Acids Res. 2001;29:246–254
  25. Peng SS, Chen CY, Shyu AB. Functional characterization of a non-AUUUA AU-rich element from the c-jun proto -oncogene mRNA: evidence for a novel class of AU-rich elements. Mol. Cell. Biol. 1996;16:1490–1499
  26. Katsanou V, Papadaki O, Milatos S, Blackshear PJ, Anderson P, Kollias G, et al. HuR as a negative posttranscriptional modulator in inflammation. Mol. Cell. 2005;19:777–789
  27. Doller A, Pfeilschifter J, Eberhardt W. Signalling pathways regulating nucleo-cytoplasmic shuttling of the mRNA-binding protein HuR. Cell. Signal. 2008;20:2165–2173

PII: S0022-2828(10)00179-3

doi: 10.1016/j.yjmcc.2010.04.016

Journal of Molecular and Cellular Cardiology
Volume 49, Issue 4 , Pages 647-654 , October 2010

Article Tools

* Image Usage & Resolution